This does not seem to fully reflect European NST practice given that some investigators may have selected these patients for pre-registration in the study because patients with triple negative and HER2+ breast cancer have a higher likelihood of pCR, which excludes them from the TAXIS trial. This evidence concerns the gene ERBB2 and breast cancer.